Avita Medical (Cambridge, U.K.) has launched its ReCell Autologous Cell Harvesting Device in the U.S.
The system is designed to threat acute thermal burns in patients who are 18 years or older. So far, 36 burns centers have started the purchase authorization process with hospital administrations, 25 burn centers have been trained and certified to use the system and 12 accounts have already placed orders and received shipments.
“We are pleased that in advance of our market launch and without any direct promotional effort the clinical and economic benefits of the ReCell System have generated strong interest and sales orders,” Erin Liberto, chief commercial officer, said in a press release. “Based on the pre-promotion demand, we are excited to see the response now that our full sales team of 20 has been deployed.”
The ReCell System uses a small amount of a patient’s skin to make Spray-On-Skin Cells in about 30 minutes to treat thermal burns. The system enzymatically and mechanically processes a small skin sample to isolate skin cells and produce the suspension of Spray-On Skin Cells.
Keratinocytes, fibroblasts and melanocytes are included in the regenerative cell suspension and help with wound healing. The suspension is sprayed directly on a second-degree burn or with an expanded skin graft on a third-degree burn to evenly distribute the skin cells.
Avita Medical’s ReCell System is designed to treat wounds up to 80 times the size of a donor skin sample.
“I could not be more pleased with the quality of individuals and the collective focus they have all devoted to the ReCell System launch,” Terry Bromley, VP of commercial operations at Avita Medical, said. “We are very delighted with the enthusiasm our highly experienced sales team has expressed for the ReCell System, and how quickly this team of professional has prepared for the U.S. launch.”
